Pharmaceutical

Nymox Pharmaceutical (NASDAQ:NYMX) reports today that the results of Phase 3 clinical studies of Fexapotide Triflutate undertaken from 2009-2016 are now published in World Journal of Urology. As quoted in the press release: According to the new publication, “In conclusion, data from these 4 U.S. studies show statistically significant long-term improvement in BPH symptoms and objective …

Nymox Pharmaceutical (NASDAQ:NYMX) reports today that the results of Phase 3 clinical studies of Fexapotide Triflutate undertaken from 2009-2016 are now published in World Journal of Urology.
As quoted in the press release:

According to the new publication, “In conclusion, data from these 4 U.S. studies show statistically significant long-term improvement in BPH symptoms and objective outcomes including significant reduction in spontaneous AUR as well as the addition of BPH surgery;” and “FT is well tolerated with an excellent safety profile. Hence, FT is a safe and efficacious clinic based treatment for BPH involving an intraprostatic injection that requires only a few minutes to administer, with no catheter nor anesthesia requirements. FT injectable represents a novel, first in class BPH treatment modality.”

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20685.27+153.09
TSXV720.89+6.23
DOW32978.33+341.14
S&P 5004129.55+71.71
NASD12046.86+306.21
ASX7105.90-49.30

COMMODITIES

Commodities
Gold1854.32+1.26
Silver22.06+0.04
Copper4.31+0.05
Palladium2072.70+64.70
Platinum958.13+9.13
Oil114.72+0.63
Heating Oil3.86+0.01
Natural Gas8.80-0.10

DOWNLOAD FREE REPORTS

×